Cardiff Oncology, Inc.
CRDF · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -0.8% | 11% | -27.8% | – |
| Cost of Goods Sold | $0 | $12 | $0 | $0 |
| Gross Profit | $0 | -$11 | $0 | $0 |
| % Margin | 100% | -9,470.2% | 100% | 100% |
| R&D Expenses | $8 | $12 | $10 | $10 |
| G&A Expenses | $4 | $0 | $4 | $3 |
| SG&A Expenses | $4 | $0 | $4 | $3 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$8 | $0 | $0 |
| Operating Expenses | $12 | $3 | $14 | $13 |
| Operating Income | -$12 | -$15 | -$14 | -$13 |
| % Margin | -9,978.3% | -12,212.4% | -13,194.5% | -8,325.8% |
| Other Income/Exp. Net | $1 | $1 | $1 | $1 |
| Pre-Tax Income | -$11 | -$14 | -$13 | -$12 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$11 | -$14 | -$13 | -$12 |
| % Margin | -9,381.7% | -11,523.1% | -12,324.8% | -7,806% |
| EPS | -0.17 | -0.21 | -0.2 | -0.25 |
| % Growth | 19% | -5% | 20% | – |
| EPS Diluted | -0.17 | -0.21 | -0.28 | -0.25 |
| Weighted Avg Shares Out | 67 | 67 | 67 | 48 |
| Weighted Avg Shares Out Dil | 67 | 67 | 48 | 48 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1 | $1 | $1 | $1 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$11 | -$15 | -$14 | -$12 |
| % Margin | -8,970% | -12,134.7% | -12,985.3% | -8,262.3% |